DSM announces license agreement with Amgen for use of DSM's XD® Cell Culture
DSM Pharmaceutical Products, the custom manufacturing and technology business
of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a
non-exclusive license agreement with Amgen Inc. for access to DSM's
proprietary XD® high cell density process patents.
PARSIPPANY, N.J., Jan. 15, 2013
PARSIPPANY, N.J., Jan. 15, 2013 /PRNewswire/ --Karen King, President of DSM
Biologics, commented "We are pleased to enter into this license agreement with
Amgen, a global leader in biopharmaceutical drug development and
manufacturing. We believe our proprietary XD^® technology will play an
important role in the next generation of biopharmaceutical manufacturing."
XD^® technology is a highly intensified cell culture process with typical
titer achievement of 8-to-10 times higher compared to current standard
biomanufacturing processes. For some products, titer improvements of up to 15
times have been achieved. It is widely applicable for multiple biological
products including proteins, fusion proteins and antibodies, and has been
successfully employed across the full spectrum of mammalian cell systems.
Alexander Wessels, President and CEO of DSM Pharmaceutical Products also
commented, "DSM continuously strives to provide its clients with added value
through our innovative service and technology offerings." With typical XD^®
titer improvement of 8-10X, a 500L bioreactor can provide a DSM licensee with
the same amount of drug substance as a 5000L stainless steel bioreactor at an
overall lower cost. DSM's proprietary technologies drive down cost, processing
times and capital requirements while increasing flexibility to meet market
demand for life saving medications. XD^® has also shown impressive results for
biosimilars and innovator drugs with respect to both volume and product
Financial terms were not disclosed.
XD^® is a registered trademark of DSM
DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials.
DSM's 22,000 employees deliver annual net sales of about € 9 billion. The
company is listed on NYSE Euronext. More information can be found at
www.dsmbiologics.com and www.dsm.com
For more information:
Guy Tiene Karen King
Director, Marketing and Communications President
DSM Pharmaceutical Products DSM Biologics
tel. +1 973 257 8160 tel. +1 973 257 8427
email email@example.com email firstname.lastname@example.org
This press release may contain forward-looking statements with respect to
DSM's future (financial) performance and position. Such statements are based
on current expectations, estimates and projections of DSM and information
currently available to the company. DSM cautions readers that such statements
involve certain risks and uncertainties that are difficult to predict and
therefore it should be understood that many factors can cause actual
performance and position to differ materially from these statements. DSM has
no obligation to update the statements contained in this press release, unless
required by law. The English language version of the press release is leading.
SOURCE DSM Pharmaceutical Products
Press spacebar to pause and continue. Press esc to stop.